Profound Medical Corp
TSX:PRN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
P
|
Pernod Ricard SA
OTC:PDRDF
|
FR |
EV/OCF
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Valuation Scenarios
If EV/OCF returns to its Industry Average (14.9), the stock would be worth CA$-28.05 (395% downside from current price).
| Scenario | EV/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -5 | CA$9.5 |
0%
|
| Industry Average | 14.9 | CA$-28.05 |
-395%
|
| Country Average | 11.9 | CA$-22.5 |
-337%
|
Forward EV/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | EV/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| CA |
|
Profound Medical Corp
TSX:PRN
|
344.8m CAD | -5 | -5.8 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
170B USD | 54.1 | 59.5 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
160.6B USD | 16.9 | 25.6 | |
| US |
|
Stryker Corp
NYSE:SYK
|
126.1B USD | 27.2 | 38.8 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
107.5B USD | 17.4 | 23.3 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
97.4B USD | 23.6 | 33.6 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
40.6B EUR | 15.8 | 19.2 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
46.3B USD | 26.5 | 43.1 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
44.7B USD | 38.1 | 42.2 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
44.1B USD | 17.7 | 25.1 | |
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
31.9B USD | 18.6 | 15.3 |
Market Distribution
| Min | 0 |
| 30th Percentile | 7.9 |
| Median | 11.9 |
| 70th Percentile | 19.5 |
| Max | 22 577.3 |
Other Multiples
Profound Medical Corp
Glance View
Profound Medical Corp. develops, manufactures and markets therapeutic platforms that combine real-time magnetic resonance imaging with directional and focused ultrasound technology for incision-free ablation of diseased tissue. The company is headquartered in Mississauga, Ontario and currently employs 146 full-time employees. The company went IPO on 2014-09-24. The firm is commercializing TULSA-PRO, which is a technology that combines real-time magnetic resonance imaging (MRI), transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while protecting the urethra and rectum to help preserve the patient’s natural functional abilities. The firm is also commercializing Sonalleve, which is a therapeutic platform for the treatment of uterine fibroids and palliative pain treatment of bone metastases.
